This is a discussion-oriented meeting and the formats of both the symposium and workshop are designed to allow ample time for stimulating discussions focused on understanding the current state of the art, knowledge gaps, and unanswered questions in the field. The ultimate goal is to achieve some convergence on defining the research priorities and opportunities that would enable us to translate our understanding of alpha-synuclein functions in health and disease to accelerate ongoing and future efforts aimed at developing effective therapies for the treatment of Parkinson’s disease and related synucleinopathies.

The first two days will consist of a series of well-structured sessions focused on critical assessment of :

  • Our current understanding of the normal functions of alpha-synuclein.
  • The short- and long-term consequences of modulating alpha-synuclein levels.
  • The role of aggregation-independent alpha-synuclein toxicity mechanisms.

On the third day, we will have a workshop that will consist of four-round table discussions which will reflect on the presentations and discussions from the symposium and focusing on :

  • Reassessing the interplay between alpha-synuclein normal functions and its role in the pathogenesis of PD and other synucleinopathies.
  • Implications of understanding Alpha-synuclein functions and regulating its levels for the development of prevention and disease modifying strategies.
  • Challenges and opportunities for the next five years.
  • New models for collaborations and consortia, including between industry-academia, to advance translational research in Parkinson’s disease.